Early use of naloxone in shock - A clinical trial

Chaim Putterman, Pinchas Halpern, Yigal Leykin, Patrick Sorkine, Eran Geller, Simon Bursztein

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Naloxone hydrochloride (N) 0.4-1.2 mg i.v. was administered during 10 episodes of shock (8 septic and 2 cardiogenic) in 9 adult patients. Shock was defined as systolic blood pressure (SBP) ≤90 mmHg and urine output <0.5 ml/h and signs and symptoms of hypoperfusion lasting for >-30 min, despite fluid loading to a CVP 5 cmH2O above baseline. N was given as early as 30 min after onset of shock and resulted in an increase of SBP from a mean of 75 ± 10 to a mean of 130 ± 25 mmHg maximum (P < 0.01). Within 10-60 min urine output increased from 16 ± 12 to 122 ± 56 ml/h, heart rate, CVP and arterial blood gas tensions remained unchanged. No side effects were observed. Naloxone, even in small doses, may improve hemodynamic parameters in human shock, provided it is administered very early.

Original languageEnglish (US)
Pages (from-to)185-190
Number of pages6
JournalResuscitation
Volume13
Issue number3
DOIs
StatePublished - 1986
Externally publishedYes

Fingerprint

Naloxone
Shock
Clinical Trials
Blood Pressure
Urine
Septic Shock
Heart Rate
Gases
Hemodynamics

Keywords

  • Naloxone
  • Shock

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Nursing(all)

Cite this

Putterman, C., Halpern, P., Leykin, Y., Sorkine, P., Geller, E., & Bursztein, S. (1986). Early use of naloxone in shock - A clinical trial. Resuscitation, 13(3), 185-190. https://doi.org/10.1016/0300-9572(86)90100-0

Early use of naloxone in shock - A clinical trial. / Putterman, Chaim; Halpern, Pinchas; Leykin, Yigal; Sorkine, Patrick; Geller, Eran; Bursztein, Simon.

In: Resuscitation, Vol. 13, No. 3, 1986, p. 185-190.

Research output: Contribution to journalArticle

Putterman, C, Halpern, P, Leykin, Y, Sorkine, P, Geller, E & Bursztein, S 1986, 'Early use of naloxone in shock - A clinical trial', Resuscitation, vol. 13, no. 3, pp. 185-190. https://doi.org/10.1016/0300-9572(86)90100-0
Putterman C, Halpern P, Leykin Y, Sorkine P, Geller E, Bursztein S. Early use of naloxone in shock - A clinical trial. Resuscitation. 1986;13(3):185-190. https://doi.org/10.1016/0300-9572(86)90100-0
Putterman, Chaim ; Halpern, Pinchas ; Leykin, Yigal ; Sorkine, Patrick ; Geller, Eran ; Bursztein, Simon. / Early use of naloxone in shock - A clinical trial. In: Resuscitation. 1986 ; Vol. 13, No. 3. pp. 185-190.
@article{5fa3564c102b44acb785e686ef023854,
title = "Early use of naloxone in shock - A clinical trial",
abstract = "Naloxone hydrochloride (N) 0.4-1.2 mg i.v. was administered during 10 episodes of shock (8 septic and 2 cardiogenic) in 9 adult patients. Shock was defined as systolic blood pressure (SBP) ≤90 mmHg and urine output <0.5 ml/h and signs and symptoms of hypoperfusion lasting for >-30 min, despite fluid loading to a CVP 5 cmH2O above baseline. N was given as early as 30 min after onset of shock and resulted in an increase of SBP from a mean of 75 ± 10 to a mean of 130 ± 25 mmHg maximum (P < 0.01). Within 10-60 min urine output increased from 16 ± 12 to 122 ± 56 ml/h, heart rate, CVP and arterial blood gas tensions remained unchanged. No side effects were observed. Naloxone, even in small doses, may improve hemodynamic parameters in human shock, provided it is administered very early.",
keywords = "Naloxone, Shock",
author = "Chaim Putterman and Pinchas Halpern and Yigal Leykin and Patrick Sorkine and Eran Geller and Simon Bursztein",
year = "1986",
doi = "10.1016/0300-9572(86)90100-0",
language = "English (US)",
volume = "13",
pages = "185--190",
journal = "Resuscitation",
issn = "0300-9572",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Early use of naloxone in shock - A clinical trial

AU - Putterman, Chaim

AU - Halpern, Pinchas

AU - Leykin, Yigal

AU - Sorkine, Patrick

AU - Geller, Eran

AU - Bursztein, Simon

PY - 1986

Y1 - 1986

N2 - Naloxone hydrochloride (N) 0.4-1.2 mg i.v. was administered during 10 episodes of shock (8 septic and 2 cardiogenic) in 9 adult patients. Shock was defined as systolic blood pressure (SBP) ≤90 mmHg and urine output <0.5 ml/h and signs and symptoms of hypoperfusion lasting for >-30 min, despite fluid loading to a CVP 5 cmH2O above baseline. N was given as early as 30 min after onset of shock and resulted in an increase of SBP from a mean of 75 ± 10 to a mean of 130 ± 25 mmHg maximum (P < 0.01). Within 10-60 min urine output increased from 16 ± 12 to 122 ± 56 ml/h, heart rate, CVP and arterial blood gas tensions remained unchanged. No side effects were observed. Naloxone, even in small doses, may improve hemodynamic parameters in human shock, provided it is administered very early.

AB - Naloxone hydrochloride (N) 0.4-1.2 mg i.v. was administered during 10 episodes of shock (8 septic and 2 cardiogenic) in 9 adult patients. Shock was defined as systolic blood pressure (SBP) ≤90 mmHg and urine output <0.5 ml/h and signs and symptoms of hypoperfusion lasting for >-30 min, despite fluid loading to a CVP 5 cmH2O above baseline. N was given as early as 30 min after onset of shock and resulted in an increase of SBP from a mean of 75 ± 10 to a mean of 130 ± 25 mmHg maximum (P < 0.01). Within 10-60 min urine output increased from 16 ± 12 to 122 ± 56 ml/h, heart rate, CVP and arterial blood gas tensions remained unchanged. No side effects were observed. Naloxone, even in small doses, may improve hemodynamic parameters in human shock, provided it is administered very early.

KW - Naloxone

KW - Shock

UR - http://www.scopus.com/inward/record.url?scp=0022611113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022611113&partnerID=8YFLogxK

U2 - 10.1016/0300-9572(86)90100-0

DO - 10.1016/0300-9572(86)90100-0

M3 - Article

C2 - 3012734

AN - SCOPUS:0022611113

VL - 13

SP - 185

EP - 190

JO - Resuscitation

JF - Resuscitation

SN - 0300-9572

IS - 3

ER -